A promising antiedematous drug for adjuvant therapy of myocardial infarction is a novel proteolytically stable peptide inhibitor of MLCK, PIK7, designed at the National Medical Research Center of Cardiology, named after Academician E.I. Chazov, Ministry of Health of the Russian Federation [17]. The gene discussed is MYLK; the disease is myocardial infarction.